Cor Vasa 2026, 68(1):73-77 | DOI: 10.33678/cor.2025.130

(Beta-blockers in patients after myocardial infarction with ejection fraction 41-49%?)

Radek Pudil
I. interní kardioangiologická klinika, Lékařská fakulta Univerzity Karlovy a Fakultní nemocnice Hradec Králové, Hradec Králové, Česká republika

Beta-blocker therapy is one of the fundamental pillars of pharmacological treatment for patients after myocardial infarction with reduced ejection fraction. It has been shown that the benefit of this therapy decreases as the ejection fraction increases. Recently, results from several studies (REBOOT-CNIC, BETAMI, DANBLOCK, and CAPITAL-RCT) and their meta-analysis have been presented, providing very favorable data demonstrating the benefit of beta-blocker therapy in patients with mildly reduced left ventricular ejection fraction. According to this analysis, a lower incidence of monitored outcomes (all-cause mortality, new myocardial infarction, or heart failure) was observed in patients treated with beta-blockers. Conversely, for patients with preserved ejection fraction, there is insufficient evidence to demonstrate a strong benefit of beta-blocker therapy.

Keywords: Betablocker therapy, Heart failure with mildly reduced ejection fraction, Myocardial infarction

Received: November 30, 2025; Revised: November 30, 2025; Accepted: December 7, 2025; Prepublished online: June 2, 2012; Published: March 15, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pudil R. (Beta-blockers in patients after myocardial infarction with ejection fraction 41-49%?). Cor Vasa. 2026;68(1):73-77. doi: 10.33678/cor.2025.130.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J 2023;44:3720-3826. Go to original source... Go to PubMed...
    2. Watanabe H, Ozasa N, Morimoto T, et al. Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. PLoS One 2018;13:e0199347. Go to original source... Go to PubMed...
    3. Rosano GMC, Teerlink JR, Kinugawa K, et al. The use of left ventricular ejection fraction in the diagnosis and management of heart failure. A clinical consensus statement of the Heart Failure Association (HFA) of the ESC, the Heart Failure Society of America (HFSA), and the Japanese Heart Failure Society (JHFS). Eur J Heart Fail 2025;27:1174-1187. Go to original source... Go to PubMed...
    4. Kotecha D, Flather MD, Altman DG, et al. Heart Rate and Rhythm and the Benefit of Beta-Blockers in Patients With Heart Failure. J Am Coll Cardiol 2017;69:2885-2896. Go to original source... Go to PubMed...
    5. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357:1385-1390. Go to original source... Go to PubMed...
    6. Sim HW, Zheng H, Richards AM, et al. Beta-blockers and renin--angiotensin system inhibitors in acute myocardial infarction managed with inhospital coronary revascularization. Sci Rep 2020;10:15184. Go to original source... Go to PubMed...
    7. Munkhaugen J, Kristensen AMD, Halvorsen S, et al. Beta-Blockers after Myocardial Infarction in Patients without Heart Failure. N Engl J Med. 2025;393:1901-1911. Go to original source... Go to PubMed...
    8. Ibanez B, Latini R, Rossello X, et al. Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction. N Engl J Med 2025;393:1889-1900. Go to original source... Go to PubMed...
    9. Rossello X, Prescott EIB, Kristensen AMD, et al. Beta blockers after myocardial infarction with mildly reduced ejection fraction: an individual patient data meta-analysis of randomised controlled trials. Lancet 2025;406:1128-1137. Go to original source... Go to PubMed...
    10. Janský P. Betablokátory v sekundární prevenci infarktu myokardu s ohledem na aktuální výsledky studií ABYSS a REDUCE-AMI. Cor Vasa 2025;67:14-17. Go to original source...
    11. Yndigegn T, Lindahl B, Mars K, et al. Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction. N Engl J Med 2024;390:1372-1381. Go to original source... Go to PubMed...
    12. Meta-analysis finds that beta-blockers improve outcomes after a heart attack in patients with mildly reduced heart function. Online. Dostupné z: https://www.escardio.org/The-ESC/Press-Office/Press-releases/Meta-analysis-finds-that-beta-blockers-improve-outcomes-after-a-heart-attack-in-patients-with-mildly-reduced-heart-function./ [citováno 2026-02-23].
    13. Beta-blockers reduced cardiovascular events in selected heart attack patients without heart failure in the BETAMI-DANBLOCK trials. Online. Dostupné z: https://www.escardio.org/The-ESC/Press-Office/Press-releases/Beta-blockers-reduced-cardiovascular-events-in-selected-heart-attack-patients-without-heart-failure-in-the-BETAMI-DANBLOCK-trials./ [citováno 2026-02-23].

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content